Hot Pursuit     17-Dec-22
Shilpa Medicare launches breast cancer drug
Shilpa Medicare announced that it has introduced Capecitabine (Capebel) dispersible tablet (DT) with technology of faster dispersion within 90 seconds to treat colorectal and metastatic breast cancer.
With the introduction of Shilpa's new brand, Capebel, patients will be required to just drop the Capecitabine tablets in 100 ml water and allow the tablets to dissolve and then drink dissolved solution. Hence from 7 to 8 tablets a day, patients just need to drink 100 ml water twice daily with dissolved tablets in it.

It is expected to change the patient's compliance and will help them continue with the correct doses with ease of drinking water and getting desired outcomes.

The product is backed by required scientific proof and comparative bioequivalence studies and is approved by Central Drugs Standard Control Organisation (CDSCO).

The company is further looking to introduce Capebel 1 gm DT in various international markets through its partners and clients.

Shilpa Medicare is a global brand in manufacturing and supplying of affordable API and formulation globally in different regulated markets.

The company's reported a consolidated net loss of Rs 18.66 crore as against a net profit of Rs 19.96 crore in Q2 FY23 over Q2 FY22. Net sales declined 11% YoY to Rs 262.91 crore in the quarter ended 30 September 2022.

The scrip fell 0.97% to end at Rs 282.20 on Friday, 16 December 2022.

Previous News
  Shilpa Medicare reports consolidated net profit of Rs 24.50 crore in the March 2024 quarter
 ( Results - Announcements 23-May-24   17:15 )
  Indices trade with minor losses; bank shares under pressure
 ( Market Commentary - Mid-Session 24-Jul-24   11:32 )
  Shilpa Medicare subsidiary’s Karnataka facility clears GMP inspection
 ( Hot Pursuit - 10-Jul-24   10:39 )
  Shilpa Biologicals receives first international market approval for Adalimumab
 ( Corporate News - 23-Jul-24   17:41 )
  Shilpa Medicare arm gets CEP from EDQM for Desmopressin
 ( Hot Pursuit - 04-Oct-24   08:40 )
  Shilpa Medicare hits record high on USFDA nod for cancer drug
 ( Hot Pursuit - 27-Aug-24   14:43 )
  Shilpa Medicare's Unit III R&D facility clears USFDA Remote Record Review
 ( Corporate News - 19-Nov-21   15:11 )
  Shilpa Medicare announces receipt of CEP from EDQM for API 'Desmopressin'
 ( Corporate News - 03-Oct-24   17:12 )
  Shilpa Pharma Lifesciences' API unit in Raichur receives GMP Certification
 ( Corporate News - 23-Jul-24   17:27 )
  Board of Shilpa Medicare approves rights issue of Rs 325 cr
 ( Corporate News - 23-Jun-23   14:41 )
  Shilpa Medicare Karnataka unit clears PMDA inspection
 ( Hot Pursuit - 04-Sep-23   10:04 )
Other Stories
  UCO Bank’s total advances jump 19% YoY in Q2 FY25
  04-Oct-24   15:15
  Vakrangee Ltd leads losers in 'A' group
  04-Oct-24   15:00
  Kamdhenu Ventures Ltd leads losers in 'B' group
  04-Oct-24   14:45
  GRSE bags Rs 226-cr LoA from West Bengal Govt
  04-Oct-24   14:40
  Volumes soar at Avenue Supermarts Ltd counter
  04-Oct-24   14:30
  Real Estate stocks edge lower
  04-Oct-24   14:00
  Auto stocks edge lower
  04-Oct-24   14:00
  Utilties stocks edge lower
  04-Oct-24   14:00
  HDFC Bank Ltd down for fifth straight session
  04-Oct-24   13:35
  Power Grid Corporation of India Ltd down for fifth straight session
  04-Oct-24   13:35
Back Top